Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment and prevention of hypokalemia,Maintenance of electrolyte balance when oral replacement is not feasible,Correction of potassium deficiency associated with diuretic therapy or other conditions
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion: 10-20 m Eq/hour, not exceeding 30 m Eq/hour or 200 m Eq/24 hours; rate depends on severity of hypokalemia and patient tolerance.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Not applicable as potassium is an electrolyte regulated by renal function; in normal renal function, steady state achieved within 24-48 hours of continuous infusion
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Potassium is primarily excreted by the kidneys; metabolism not applicable. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water. Sodium chloride does not undergo metabolism.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >90% as potassium ions; minimal biliary/fecal (<5%)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Minimal; potassium ions are not significantly protein-bound (<5%)
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Approximately 0.5 L/kg; represents total body water distribution; clinical note: ~98% intracellular, 2% extracellular
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral (if applicable): 100% (well absorbed); IV: 100%
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR < 10 m L/min: avoid or use with extreme caution, reduce dose by 75%.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment required; monitor for acidosis in severe hepatic impairment.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion: 0.5-1 m Eq/kg/day, maximum rate 1 m Eq/kg/hour; not to exceed 30 m Eq/day in neonates.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use lower initial doses; monitor renal function and serum potassium closely; avoid rapid infusion due to increased risk of hyperkalemia.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Concentrated potassium chloride injections are contraindicated and must be diluted prior to administration. Rapid intravenous administration may cause fatal hyperkalemia and cardiac arrest. Do not administer undiluted.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor serum potassium levels and ECG frequently during administration. Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Avoid rapid infusion; may cause local venous irritation. Do not use plastic container in series connections.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hyperkalemia, severe renal failure, untreated Addison's disease, severe hemolytic reactions, hyperkalemia due to any cause, or known hypersensitivity to any component.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, tomatoes, salt substitutes) unless directed by clinician, as excessive intake can lead to hyperkalemia. Grapefruit juice has no significant interaction with potassium chloride but caution with other medications. Dextrose content (5%) may affect glycemic control in diabetics; monitor blood glucose.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Potassium chloride administration is not considered teratogenic. Normal electrolyte balance is critical for fetal development; however, hyperkalemia or hypokalemia may lead to adverse fetal effects. Potassium supplementation should be used to correct hypokalemia, avoiding both deficiency and excess. No specific malformations are attributed to potassium chloride. First trimester: No known risks when used appropriately. Second and third trimesters: Use as needed to maintain normal potassium levels; overdose may cause fetal arrhythmias.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Breastfeeding safety: Potassium chloride is a normal component of breast milk. Supplementation to correct maternal deficiency is considered safe. M/P ratio: Not available; potassium is actively transported into milk, but maternal dose does not significantly affect infant serum levels. Caution with high doses due to potential for maternal hyperkalemia.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pharmacokinetics of potassium are altered in pregnancy due to increased renal blood flow and GFR, leading to enhanced clearance. Therefore, higher doses may be required to achieve target serum levels in hypokalemic pregnant women. However, dosing must be individualized based on serum potassium monitoring; no fixed dose adjustment recommendation exists. Caution to avoid hyperkalemia, especially in preeclampsia or renal impairment.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Always confirm patency of IV line before infusion due to risk of phlebitis and extravasation. Monitor serum potassium and cardiac telemetry during infusion, especially in patients with renal impairment or on digoxin. Do not administer IV potassium undiluted or via bolus; maximum infusion rate is 10 m Eq/hour via peripheral line, 20 m Eq/hour via central line. In patients with severe hypokalemia (<2.5 m Eq/L), consider continuous cardiac monitoring and more aggressive replacement under ICU setting. Note that dextrose-containing solutions may transiently lower serum potassium via insulin-mediated cellular shift.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is given through a vein (IV) to replace potassium and provide fluids.,Report any pain, redness, or swelling at the IV site immediately.,Inform your doctor if you have kidney problems, heart disease, or are taking digoxin or diuretics.,You may need regular blood tests to check your potassium levels and kidney function.,Do not consume potassium-rich foods or supplements unless advised by your doctor, as it may cause dangerously high potassium levels.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: Intravenous infusion: 10-20 m Eq/hour, not exceeding 30 m Eq/hour or 200 m Eq/24 hours; rate depends on severity of hypokalemia and patient tolerance.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride administration is not considered teratogenic. Normal electrolyte balance is critical for fetal development; however, hyperkalemia or hypokalemia may lead to adve. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.